首页 > 技术支持 > 文献速递

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy

Cancer Cell
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the basis of variable patient responses remains unclear. A longitudinal single-cell RNA sequencing atlas of 441 samples from 241 patients across ten cancer entities maps treatment-associated remodeling of the tumor immune microenvironment (TIME). Four conserved TIME subtypes are defined, and transitions during therapy track response better than the baseline state. A 59-gene signature predicted response and survival.

Related products

Catalog No. Product Name Description Target
HV974011 Recombinant Human CD274/PD-L1/B7-H1 Protein Recombinant Human CD274/PD-L1/B7-H1 Protein, C-His (HV974011) expressed in Mammalian Cells, spanning Met1-Arg238. Purity: >90% by SDS-PAGE. Highlights ●His-Tagged — N-terminal 6×His tag for IMAC purification. ●Mammalian Expression — Proper folding and native glycosylation. ●High Purity — >90% purity verified by SDS-PAGE. B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1